On Oct. 15, 2021, Merck announced that the European Medicines Agencyﾒs Committee for Medicinal Products for Human Use (CHMP) had recommended the approval of VAXNEUVANCEﾙ (Pneumococcal 15-valent Conjugate Vaccine) for active immunization for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older.